Archive
145 evidence-based reports across medicine, nutrition, mental well-being, chronic conditions, and healthcare technology.
Showing 12 of 145 stories · page 2 of 13
Orzeyful, Takeda's novel orexin-2 receptor agonist, shows 73% reduction in daytime sleep attacks in Phase 3. Learn how it differs from traditional stimulants and what the side-effect profile looks like.
A Phase 3 trial finds psilocybin significantly reduces chemotherapy-induced peripheral neuropathy pain. Learn about dosing protocols, side effects, and when this treatment might become available.
Roughly half of men on BPH drugs see their symptoms return after years of control. The 2026 procedural ladder — UroLift, Rezum, water vapor, PAE, and the newer iTind — has matured into a real set of options that work better than medications and avoid the sexual side effects of traditional surgery.
The most common CPAP complaint is that the mask fits when you put it on but leaks by hour two. The cause is jaw relaxation during deep sleep, not the mask itself. Here is the 2026 fix ladder: chin strap, hybrid mask, mouth taping, and a new European pill that may change everything.
The FDA approved daraxonrasib in August 2026, and patients in the pivotal trial lived twice as long as those on chemo. The price tag, however, is roughly $480,000 a year. Here is who qualifies, how the drug works, and what the cost really means.
A nationwide estradiol patch shortage has pushed pharmacies to substitute Dotti, Sandoz, and Mylan generics, and thousands of women are reporting migraines, hot-flash returns, and breakthrough bleeding. Here is what's happening, what to ask for at the pharmacy, and what the alternatives are.
President Trump nominated Dr. Heidi Overton, a top domestic policy aide and MAHA-aligned abortion opponent, to be the next FDA Commissioner. If confirmed, she will inherit a backlog of decisions on supplements, GLP-1 compounding, and pediatric vaccines. Here is what is likely to change and what is not.
A small CRISPR Therapeutics trial dropped LDL by roughly 50 percent with a single infusion, and the effect held for a full year. Here is how in-body gene editing differs from statins, enlicitide, and inclisiran, who could qualify, and what the long-term unknowns are.
U.S. IVF cycles now average $29,000 to $54,000, and most states do not require insurance coverage. A 2026 KFF Health News investigation found that the number of Americans going to Greek and Spanish clinics grew by 37 percent last year. Here is what they pay, what they get, and the legal and medical realities.
In August 2026, Pennsylvania confirmed two measles deaths. The CDC Director publicly challenged the state's count, Health Secretary RFK Jr. issued mixed messaging, and the clash exposed the fracture between federal and state public-health authority.
Medicare launched a GLP-1 pilot in 2026 with a $50 monthly cap that should have expanded access to Wegovy and Zepbound. NPR found on August 30, 2026 that the eligibility criteria exclude the patients with the most serious obesity-related illnesses. Here is who qualifies, who does not, and what to do if you are excluded.
Moderna's mRNA-4157 plus Merck's Keytruda cut the risk of melanoma recurrence by about half in high-risk patients in 2024. The 2026 update from ASCO and a phase 3 trial expansion show the approach is moving toward broader approval. Here is the science, the trial, and what to expect.
